|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TTC9C |
Gene summary for TTC9C |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TTC9C | Gene ID | 283237 |
| Gene name | tetratricopeptide repeat domain 9C | |
| Gene Alias | TTC9C | |
| Cytomap | 11q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q8N5M4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 283237 | TTC9C | LZE7T | Human | Esophagus | ESCC | 4.87e-03 | 1.68e-01 | 0.0667 |
| 283237 | TTC9C | LZE24T | Human | Esophagus | ESCC | 3.91e-13 | 3.99e-01 | 0.0596 |
| 283237 | TTC9C | LZE6T | Human | Esophagus | ESCC | 3.79e-06 | 3.12e-01 | 0.0845 |
| 283237 | TTC9C | P2T-E | Human | Esophagus | ESCC | 4.36e-16 | 2.53e-01 | 0.1177 |
| 283237 | TTC9C | P4T-E | Human | Esophagus | ESCC | 3.28e-28 | 6.73e-01 | 0.1323 |
| 283237 | TTC9C | P5T-E | Human | Esophagus | ESCC | 7.49e-19 | 3.54e-01 | 0.1327 |
| 283237 | TTC9C | P8T-E | Human | Esophagus | ESCC | 4.62e-16 | 3.36e-01 | 0.0889 |
| 283237 | TTC9C | P9T-E | Human | Esophagus | ESCC | 7.98e-12 | 2.99e-01 | 0.1131 |
| 283237 | TTC9C | P10T-E | Human | Esophagus | ESCC | 2.27e-18 | 2.63e-01 | 0.116 |
| 283237 | TTC9C | P11T-E | Human | Esophagus | ESCC | 5.04e-07 | 3.21e-01 | 0.1426 |
| 283237 | TTC9C | P12T-E | Human | Esophagus | ESCC | 3.44e-15 | 2.69e-01 | 0.1122 |
| 283237 | TTC9C | P15T-E | Human | Esophagus | ESCC | 5.00e-09 | 2.08e-01 | 0.1149 |
| 283237 | TTC9C | P16T-E | Human | Esophagus | ESCC | 9.85e-11 | 2.57e-01 | 0.1153 |
| 283237 | TTC9C | P17T-E | Human | Esophagus | ESCC | 2.79e-04 | 2.57e-01 | 0.1278 |
| 283237 | TTC9C | P19T-E | Human | Esophagus | ESCC | 5.97e-05 | 4.63e-01 | 0.1662 |
| 283237 | TTC9C | P20T-E | Human | Esophagus | ESCC | 4.07e-15 | 3.79e-01 | 0.1124 |
| 283237 | TTC9C | P21T-E | Human | Esophagus | ESCC | 4.15e-17 | 3.67e-01 | 0.1617 |
| 283237 | TTC9C | P22T-E | Human | Esophagus | ESCC | 2.14e-11 | 2.10e-01 | 0.1236 |
| 283237 | TTC9C | P23T-E | Human | Esophagus | ESCC | 5.56e-16 | 3.79e-01 | 0.108 |
| 283237 | TTC9C | P24T-E | Human | Esophagus | ESCC | 7.84e-10 | 2.33e-01 | 0.1287 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TTC9C | SNV | Missense_Mutation | c.451A>T | p.Thr151Ser | p.T151S | Q8N5M4 | protein_coding | deleterious(0.01) | benign(0.219) | TCGA-BH-A0HW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| TTC9C | SNV | Missense_Mutation | novel | c.463N>T | p.Leu155Phe | p.L155F | Q8N5M4 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-C8-A26W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| TTC9C | SNV | Missense_Mutation | c.343N>A | p.Gly115Arg | p.G115R | Q8N5M4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E2-A15A-06 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
| TTC9C | SNV | Missense_Mutation | c.479N>C | p.Arg160Thr | p.R160T | Q8N5M4 | protein_coding | deleterious(0.04) | benign(0.006) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| TTC9C | SNV | Missense_Mutation | rs539570547 | c.275N>A | p.Arg92Gln | p.R92Q | Q8N5M4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-VS-A959-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| TTC9C | SNV | Missense_Mutation | rs757600351 | c.26N>G | p.Gln9Arg | p.Q9R | Q8N5M4 | protein_coding | tolerated(0.26) | benign(0) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TTC9C | SNV | Missense_Mutation | novel | c.493N>A | p.Leu165Ile | p.L165I | Q8N5M4 | protein_coding | tolerated(0.05) | benign(0.072) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TTC9C | SNV | Missense_Mutation | novel | c.401N>T | p.Ala134Val | p.A134V | Q8N5M4 | protein_coding | deleterious(0.03) | probably_damaging(0.994) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| TTC9C | SNV | Missense_Mutation | novel | c.260N>A | p.Pro87His | p.P87H | Q8N5M4 | protein_coding | tolerated(0.46) | benign(0.005) | TCGA-AX-A3G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TTC9C | SNV | Missense_Mutation | rs778887758 | c.271N>A | p.Glu91Lys | p.E91K | Q8N5M4 | protein_coding | deleterious(0.02) | possibly_damaging(0.46) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |